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well as an economic burden to patients and the commu-
nity. DES is considered to arise from the interplay of inad-
equate tear production, increased tear evaporation, and 
altered composition of the tear fi lm. The underlying bio-
chemical and physiological events in the development of 
DES and precise composition of the human tear fl uid are 
only partially understood. Until now the model of the tear 
fi lm has been a three-layered structure ( 2, 3 ): the inner 
mucin-enriched phase and the middle aqueous layer with 
soluble proteins form a gel-like structure while the outer-
most layer consists of lipids. On the basis of analysis of 
meibomian gland secretions, the lipid layer is suggested to 
be composed of wax esters, sterol esters, and polar lipids 
( 4, 5 ). It has been suggested, based on the hydrophobic ef-
fect, that the charged (polar) phospholipids are disposed 
adjacent to the aqueous-mucin layer and, externally to 
this, a layer composed of nonpolar lipids, such as choles-
teryl esters and triglycerides, face the tear-air interface 
( 6–8 ). This type of lipid organization is believed to strongly 
oppose evaporation. Yet, the ocular and mucin compo-
nents become vulnerable to lipid contamination, which 
would lead to dewetting of the corneal epithelium. A 
mechanism to organize and maintain homeostasis of the 
lipid layer and to prevent epithelial or mucin contamina-
tion is needed. Indeed, lipocalin, one such kind of pro-
tein, has been confi rmed to effi ciently remove lipids from 
the corneal surface ( 9 ). Yet this observation does not ex-
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 Dry eye syndrome (DES), the most common ocular dis-
order that affects around 14% of individuals aged 65 ± 10 
years ( 1 ), poses a considerable public health problem as 
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 Tear fl uid samples 
 Onion vapor-induced tear fl uid samples were collected from 
the lower conjunctival sac of two healthy subjects by means 
of 25 µL micropipettes (Blaubrand Intramark; Brand GMBH, 
Wertheim, Germany) causing minimal conjunctival irritation. 
The samples were immediately cooled to 4°C, pooled, and stored 
at   70°C until analyzed. Total protein content in tear fl uid was 
9.6 mg/ml as analyzed by the Lowry method, and of that, the 
PLTP mass was 9.6   g/ml. This study was performed according 
to the principles of the Helsinki Declaration and approved by the 
Ethics Review Committee of the Department of Ophthalmology, 
University of Helsinki. Informed consent was obtained from each 
subject. The permission to use tissue samples was obtained from 
the Finnish National Authority for Medicolegal Affairs. 
 Immunohistochemistry 
 Sections of formalin-fi xed, paraffi n-embedded tissues containing 
the lacrimal gland and the adjacent conjunctiva were incubated with 
monoclonal antibodies to PLTP, MAb59 and MAb66. The sections 
were processed in a microwave oven (2 × 5 min at 900 W) and treated 
with a methanol-perhydrol solution for 30 min to block endogenous 
peroxidase activity. Immunohistochemical staining was performed 
using a commercial Elite ABC Kit (Vectastain, Vector Laboratories, 
Burlingame, CA). The sections were blocked with CAS-Block solu-
tion (Zymed, San Francisco, CA) for 20 min, followed by incubation 
overnight at 4°C with monoclonal MAb 59 or MAb66 antibody 
diluted 1:1000 in Chem Mate (Dako, Glostrup, Denmark). Nonim-
munized mouse serum served as a primary antibody source in all 
control staining. The slides were rinsed three times (15 min each) 
with phosphate-buffered saline (PBS; pH 7.2) between every stain-
ing step, and all incubations were carried out in a moist chamber. 
The bound peroxidase activity was visualized with a specifi c sub-
strate, 3-amino-9-ethylcarbazole (Sigma) solution (0.2 mg/ml in 
0.05 M acetate buffer containing 0.03% perhydrol; pH 5). The slides 
were stained with hematoxylin, washed with distilled water, and 
mounted in Aquamount (BDH, Poole, UK). 
 Heparin trapping of PLTP 
 To determine possible PLTP-protein interactions in tear fl uid, 
Heparin-Sepharose affi nity chromatography was used. Briefl y, 
pooled tear fl uid samples in a total volume of 400 µl were applied to 
a 1 ml HiTrap Heparin column (GE Healthcare, Buckinghamshire, 
UK) that was equilibrated with buffer A (25 mM Tris-HCl buffer, pH 
7.4 containing 1 mM EDTA). The column was washed with buffer A 
(fl ow rate 0.5 ml/min), and the bound material was eluted with a 
0.5 M NaCl in buffer A (fl ow rate 0.5 ml/min; fraction size 1.0 ml). 
The active PLTP fractions were combined and dialyzed against 
buffer A and then applied to same 1 ml HiTrap Heparin column. 
The bound PLTP was eluted with a linear 0–0.5 M NaCl gradient 
(fl ow rate 0.5 ml/min; fraction size 0.5 ml). The fractions were 
analyzed for PLTP activity ( 18 ). The active fractions were pooled 
and concentrated with nanosep 10K omega system (Pall Life 
Sciences, UK). Lyophilized material was loaded to 12.5% SDS-PAGE 
gel and stained with Coomassie R-250. The detected protein bands 
were cut apart and transferred to mass spectrometry. 
 Measurements of PLTP activity 
 PLTP activity was recorded by measuring the transfer of 14 C -PC 
from radiolabeled PC vesicles to unlabeled HDL3 acceptors, with 
minor modifi cations ( 10 ). 
 Immunoprecipitation of PLTP-protein complex with 
monoclonal and polyclonal antibodies against PLTP and 
tear fl uid mucin 
 Immunoprecipitation was used to confi rm or exclude the 
binding partners for PLTP in human tear fl uid. Both tear fl uid 
clude the possibility that other tear proteins are capable of 
performing similar functions. 
 Earlier we have shown that active form (high active; HA ) 
of the phospholipid transfer protein (PLTP), a glycopro-
tein with phospholipid transfer activity, is a normal com-
ponent of the human tear fl uid ( 10 ). This fi nding has 
been recently verifi ed with liquid chromatography (LC) 
MALDI-TOF mass spectrometry studies by Li et al. ( 11 ). 
PLTP was originally found in plasma, where it has an im-
portant role in lipoprotein metabolism ( 12 ). In plasma, 
PLTP transfers phospholipids, but not neutral lipids, be-
tween lipoprotein particles ( 13 ). The PLTP gene is also 
highly expressed in alveolar type II cells and is induced 
during hypoxia and in emphysema ( 14 ), indicating sur-
face protective properties. Notably human lung tissue, 
where PLTP is found in an air-water environment (i.e., 
similar to tear fl uid), displays high PLTP expression levels 
compared with other tissues. 
 We have been unable to unambiguously demonstrate 
the function of PLTP in tear fl uid. To shed light on the 
function of PLTP, we fi rst examined the cellular site for 
PLTP secretion into the tear fi lm. To elucidate the func-
tion of PLTP, we then searched the proteins that are pos-
sibly interacting and forming a functional complex with 
PLTP in the human tear fl uid. Here we demonstrate that 
human tear fl uid PLTP is secreted form lacrimal gland, 
and it interacts with mammalian mucins. Our data suggest 
that PLTP has an important role in the maintenance of 
lipid balance of the human tear fl uid and could in part 
attenuate the development of DES. 
 EXPERIMENTAL PROCEDURES 
 Protein samples and antibodies 
 PLTP was purifi ed from human plasma as described ( 15, 16 ). 
In the present study, the purifi ed active PLTP was used in experi-
ments. Mouse monoclonal (MAb59 and MAb66 IgG) and rabbit 
polyclonal (R290 IgG) antibodies against human PLTP were pro-
duced as described earlier ( 13 ). A soluble form of ovomucin was 
purifi ed from egg-white as described earlier ( 17 ). 
 Bovine submaxillary gland mucin (BSM; type I-S) and lac-
toperoxidase were from Sigma (St. Louis, MO), and lysozyme was 
from Abcam (Cambridge, UK). Monoclonal antibodies against 
lipocalin and serum amyloid A were from Abcam, and lactoper-
oxidase and proline rich-protein 1 monoclonal antibodies were 
from Sigma. Monoclonal mouse anti-human mucin 5AC (MUC 
5AC, clone 2-12M1) was purchased from AbD Serotec (Oxford, 
UK), and the polyclonal rabbit anti-MUC5B antibody was from 
Sigma Prestige Antibodies (St. Louis, MO). 
 Enzyme conjugated secondary antibodies, goat anti-mouse 
IgG Horseradish peroxidase (HRP), and goat anti-rabbit IgG 
HRP were purchased from Bio-Rad (Bio-Rad Laboratories, 
CA). 
 Lacrimal gland samples 
 Pieces of main lacrimal gland and the adjacent conjunctiva 
were obtained from nine subjects with whom the lacrimal gland 
was excised for diagnostic purposes (one prominent, three suspi-
cious for sarcoidosis, three excised with removal of prolapsed 
orbital fat, and two lid tumors with no involvement of the lacri-
mal gland). 
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and 0.5 ml fractions were collected for radioactivity and phos-
pholipid and protein measurements. Radioactivity of the col-
lected fractions was measured with liquid scintillation counting 
(Wallac LS Counter, Turku, Finland). Phospholipid concentra-
tion was assayed using a commercial kit (DiaSys, Holzheim, 
Germany). Dot-blot analysis of the proteins was performed as 
described above using anti-PLTP and anti-mucin antibodies. 
 Western blot analysis 
 Purifi ed active PLTP was run on SDS-PAGE and electrically 
transferred to a nitrocellulose membrane (400 mA for 45 min) 
using 0.1 M Tris with 0.192 M glycine in 20% methanol as a trans-
fer buffer. The membrane was blocked with milk powder (5% 
w/v in TBS, 0.05% Tween, pH 7.5) for 1 h at room temperature. 
Pure candidate proteins revealed by mass spectrometry were then 
added and incubated overnight at 4°C with gentle mixing. Un-
bound protein was removed by washing the membrane twice with 
TBS-Tween buffer. Candidate proteins were separately studied 
for their possible binding to PLTP with specifi c antibodies, and 
the membranes were fi nally subjected to electrochemilumines-
cence detection. 
 RESULTS 
 PLTP is secreted from the lacrimal gland 
 Given our observation on the presence of PLTP in hu-
man tear fl uid ( 10 ), we fi rst investigated the cellular origin 
of PLTP. Sections of isolated lacrimal glands were immu-
nohistochemically stained with monoclonal antibodies to 
PTLP (MAb59 and MAb66). The staining patterns were 
similar for all nine lacrimal glands studied and for both 
antibodies ( Fig. 1A -C ). The basal cells of intraglandular 
ducts gave a positive, granular staining pattern. Accumu-
lation of secreted PLTP was also seen in the lumen ( Fig. 
1B, C ). Neither control experiments with nonimmunized 
mouse serum ( Fig. 1D ) nor the secondary antibody alone 
(data not shown) show staining. 
 Heparin affi nity separation of PLTP and identifi cation 
of putative PLTP-binding proteins with MALDI-TOF 
mass spectrometry 
 To identify protein-protein interaction partners of PLTP 
we used heparin affi nity chromatography to separate PLTP 
from the tear fl uid. Following two consecutive Heparin-
Sepharose (H-S) affi nity separations, fractions containing 
active PLTP were collected and separated on SDS-PAGE 
gels for MALDI-TOF mass spectrometry (see supplemen-
tary data). Immunoblotting using Mab59 confi rmed the 
presence of PLTP in the SDS-PAGE gels ( Fig. 2A ). However, 
Coomassie blue and silver staining of the SDS-PAGE gel 
displayed several bands ( Fig. 2 and supplementary Fig. I). 
For a better resolution of the higher molecular weight 
proteins, such as mucins, we also applied the PLTP-con-
taining H-S fractions on a 4–12% gradient gel. Silver 
staining revealed a protein band migrating in the high 
molecular weight position ( Fig. 2B, arrow), which was later 
identifi ed by immunoblotting as mucin (supplementary 
Fig. II). Bands from 12.5% Coomassie-stained SDS-PAGE 
(supplementary Fig. I) were excised and subjected to 
MALDI-TOF analysis. Subsequent database searches yielded 
samples and pure proteins identifi ed by mass spectrometry were 
studied. Immunoprecipitation of the PLTP was performed using 
Protein G. Briefl y, anti-PLTP MAb 59 or rabbit polyclonal anti-
PLTP (R290) was added to washed Protein G (100 µl) and incu-
bated with gentle mixing for 60 min at room temperature, after 
which the beads were washed two times with 500 µl of TBS-Tween. 
Either pooled tear fl uid samples (100 µl) or purifi ed active PLTP 
and candidate proteins were added to the beads and incubated 
at 4°C overnight with gentle mixing. The beads were recovered, and 
the supernatants were collected. The beads were washed twice 
(0.01 M Tris, pH 8.0 and 0.05 M Tris, pH 7.4). Protein G-anti-
PLTP IgG bound material and supernatants were analyzed with 
SDS-PAGE using buffer with or without 2 mM   -mercaptoethanol. 
Adhered proteins were detected with Western blot analyses. Im-
munoprecipitation of the tear fl uid PLTP-mucin complex was 
also performed using polyclonal anti-MUC5B antibody. Separa-
tion on nonreducing 5% SDS-PAGE was done for mucin. PLTP 
was analyzed using 12.5% SDS-PAGE under reducing conditions. 
The mucins were detected with the monoclonal antibody 5AC 
(see above) and PLTP with MAb 59. 
 Dot-blot analysis 
 The dot-blot assay was used to determine the PLTP-mucin in-
teractions. Briefl y, increasing concentrations (0–45 µg/well) of 
either ovomucin (OVM) or BSM were transferred onto nitrocel-
lulose membranes using a Minifold (Amersham Pharmacia Bio-
tech) slot blot apparatus. The membranes were blocked with 
defatted milk (5% w/v in TBS, 0.1% Tween 20, pH 7.5) and 
washed twice with TBS-Tween 20. Membranes were incubated 
with HA-PLTP (25 µg) and controls without PLTP over night 
at 4°C, and then membranes were washed with TBS-Tween 20. 
Bound PLTP protein was detected by using monoclonal anti-
PLTP MAb 59 antibody as above. Bovine mucin and ovomucin 
were detected with the monoclonal anti-MUC5AC antibody. 
 Phospholipidation of BSM 
 BSM and egg-white OVM were phospholipidated using the 
cholate dialysis method ( 19 ). In brief, 1.27 mg of egg yolk phos-
phatidylcholine [EggPC, Sigma, 100 mg/ml stock in chloroform 
methanol, 9:1 (v/v)] and approximately 750 cpm of  14 [C]DPPC 
in toluene (Amersham CFA, UK) per nmol of phospholipids 
were added to a glass vial. The organic solvent was evaporated 
under nitrogen at room temperature, 1 ml of BSM or OVM (1 
mg/ml in PBS) was added, and the mixture was carefully vor-
texed. Sodium cholate (stock solution 725 mM in 10 mM Tris 
buffer containing 1 mM EDTA and 140 mM NaCl, pH 7.4 TBS) 
was used to solubilize the lipids (fi nal concentration 20 mM), 
and the mixture was gently vortexed to avoid foaming. After an 
incubation of 20 min at 24°C with shaking, the mixture was ex-
tensively dialyzed to remove cholate using a 12–14 kDa cut-off 
dialysis membrane. Protein-to-lipid ratio of the preparation was 
1:100 (mol/mol). 
 Size exclusion chromatography of mucin-PC and PLTP 
 The total volume of mucin-PC after cholate dialysis was 1.32 
ml, which was divided into four equal aliquots of 330 ul. Two of 
the aliquots were incubated together with purifi ed active PLTP 
(6 µg/ml fi nal concentration) for 30 min at room temperature 
with occasional mixing. All four samples were subjected to fast-
performance liquid chromatography on a Superose 6HR size-
exclusion column (Amersham Pharmacia Biotech). The column 
was equilibrated with PBS or PBS-Tween 20 (0.05%) and cali-
brated using protein standards (BioRad, Richmond, VA) with 
molecular weights in 1.35–670 kDa range. Size exclusion chro-
matography (SEC) was performed at a fl ow rate of 0.5 ml/min, 
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observation was that incubation of PLTP with lysozyme re-
duced the binding of PLTP to the H-S column (data not 
shown), suggesting some degree of masking of the hepa-
rin-binding domain of PLTP protein or that lysozymes 
might compete with PLTP for heparin binding sites in the 
column. 
 PLTP forms a complex with human tear fl uid mucins 
 Finally, as ocular surface mucins may become contami-
nated by lipids, the interaction of PLTP with human tear 
fl uid mucins was studied using an immunoprecipitation 
assay for PLTP. Mucin was not detectable in mass spec-
trometry analysis (see above) because ocular mucin did 
not enter the 12.5% SDS-PAGE gel due to its high appar-
ent molecular weight (about 220 kDa). The amount of 50 
  l of human tear fl uid was incubated with polyclonal anti-
PLTP antibody (R 290) (1 mg) in the presence of Protein 
G. The immunoprecipitate was collected and analyzed by 
Western blotting using monoclonal antibodies against 
PLTP and mucin. The results confi rmed direct interaction 
between PLTP and ocular mucins ( Fig. 3 ). The existence 
of a PLTP-ocular mucin complex was also investigated 
using the polyclonal anti-mucin antibody MUC5B. The 
results demonstrated that the immunoprecipitate, in addi-
tion to mucin, also contained PLTP. However, the com-
mercial antibody used was relatively weak in its ability for 
immunoprecipitation (data not shown). 
 PLTP interacts with BSM but not with OVM 
 Many studies have used commercially available mucins 
as substitutes for ocular mucins, such as BSM. Prompted 
by the fi nding that active PLTP interacted directly with 
ocular mucins in human tear fl uid, we further studied the 
feasibility of this interaction using purifi ed BSM as well as 
nonmammalian OVM. To study direct binding of these 
mucins with PLTP, a dot-blot analysis was carried out. 
These results demonstrated that purifi ed, active PLTP was 
directly bound in a concentration-dependent manner to 
BSM, whereas OVM failed to interact with active PLTP 
( Fig. 4 ). 
 Characterization of the mucin-PLTP interaction 
 To approach possible functional implications for 
mucin-PLTP interaction in vivo , we designed an in vitro ex-
perimental setup in which a phospholipidation protocol 
was used to generate mucin-phospholipid complex (using 
both bovine mucin and ovomucin). The complex, also 
containing trace amounts of  14 [C]DPPC, was incubated 
together with purifi ed PLTP and PLTP distribution was 
investigated using size exclusion chromatography (SEC). 
Approximately 80% of the radioactive label was recovered 
from the BSM-PC complex after cholate dialysis.  Fig. 5 
shows the SEC elution profi le of the mucins-PC-PLTP sam-
ples in PBS ( Fig. 5A and  5C for BSM and OVM, respec-
tively) and PBS-Tween 20 ( Fig. 5B and  5D ). When elution 
was performed with PBS, PLTP coeluted with BSM-PC in 
a broad range. However, BSM,  14 [C]DPPC, cold PC, and 
PLTP coeluted in fraction 17, suggesting a complex for-
mation between these components ( Fig. 5A ). In these ex-
signifi cant hits for lactotransferrin, lactoperoxidase, pro-
line-rich protein 1, and lysozyme C (supplementary Table 
I). In addition, lipocalin-1 and serum amyloid A were de-
tected in some samples (data not shown). All these pro-
teins have previously been detected in tear fl uid and 
may represent protein-protein interaction partners to 
PLTP. However, it is also possible that these proteins 
appear in the PLTP fraction due to direct interaction 
with the immobilized heparin. To answer this question, 
we investigated the interactions between these proteins 
and PLTP by immunoblotting and PLTP immunopre-
cipitation analysis. 
 PLTP does not interact with lysozyme-C, lactoperoxidase, 
lipocalin, or serum amyloid A 
 We used coimmunoprecipitation and Western blotting 
to confi rm the interaction of PLTP with the proteins co-
eluted in H-S chromatography and identifi ed by MALDI-
TOF mass spectrometry. After several immunoprecipitation 
experiments both with and without detergent (0.1% Tri-
ton X-100), no unambiguous binding was observed be-
tween lipocalin or serum amyloid A. A very weak band 
for lysozyme and lactoperoxidase was observed, and these 
protein pairs (i.e., PLTP-lysozyme and PLTP-lactoperoxi-
dase) were further analyzed by direct binding assays. In 
brief, 2   g of each protein (PLTP and lysozyme or PLTP 
and lactoperoxidase) were incubated and subjected to 
PLTP pull-down assay as described above. The results 
clearly demonstrated that direct binding was not evident 
(data not shown). Although direct binding between PLTP 
and the two proteins could not be observed, an interesting 
 Fig.  1. Production of human tear PLTP in lacrimal glands. A: 
Histological sections of paraffi n-embedded human lacrimal gland 
stained with hematoxylin-eosin and with MAb59 monoclonal anti-
body to PLTP. Basal cells of intraglandular ducts display positive 
staining against PLTP. B and C: Accumulation of secreted PLTP in 
the lumen (thick arrows) and positively stained basal cells (thin 
arrows) as demonstrated with strong MAb59 (B) and MAb66 (C) 
immunostaining. D: Nonimmunized mouse serum showed no 
staining of the lacrimal glands. At least 10 microscopic fi elds were 
visualized for each sample and antibody used. B, basal cell; L, lu-
men; PLTP, phospholipid transfer protein. 
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min coincubation signifi cantly improved PLTP elution. A 
longer incubation caused a similar recovery of PLTP to 
that when PBS-Tween was used as an elution buffer. Our 
experience in purifi ed PLTP fractionation is that PLTP 
can nonspecifi cally interact with the column matrix in the 
absence of Tween and when an interaction partner is miss-
ing (unpublished observations). This fi nding strongly in-
dicates that PLTP interacts with BSM with or without lipids 
(interaction with phospholipidated mucin occurs faster 
and could be more stable). Further, PLTP does not inter-
periments, lipidated ovomucin behaved similarly with 
bovine mucin. OVM-PC elutes in two major peaks around 
fractions 18 and 26. PLTP elutes in the same three peaks 
observed in the BSM-PC incubation, two of the peaks mir-
roring the mucin ones. The coelution of all three compo-
nents—OVM, PLTP, and radiolabeled phospholipids in 
fractions 17–20—suggests that the lipidated ovomucin can 
form a complex with PLTP. When 0.05% Tween 20 was 
used in the elution buffer (PBS), PLTP was released from 
the complex with mucins (both BSM and OVM) and 
eluted around the apparent molecular weight of 160 kDa, 
supporting our earlier observations ( 15 ). When used in 
excess, phospholipids interacting with the mucins could 
be displaced by Tween 20, a detergent with very high af-
fi nity for hydrophobic sites. This result was shown by the 
change in the phospholipid elution profi le ( Fig. 5B ). 
When we used lower lipid concentration in the lipidation 
process, the displacement of excess lipids by the detergent 
was no longer visible (see OVM in  Fig. 5D ), but radioactiv-
ity in the PLTP fraction 32 doubled compared with the 
BSM-PC-PLTP sample eluted in PBS. SEC analysis of non-
lipidated ovomucin and PLTP interaction was used as a 
negative control for this experimental setup.  Fig. 5E shows 
elution profi le of OVM and PLTP comixture in PBS and 
PBS-Tween, respectively. PLTP elutes in fractions corre-
sponding to molecular weight of 160 kDa when PBS-Tween 
is used, whereas this elution profi le disappears when we 
used PBS in the absence of detergent. The same experi-
ments were conducted with nonlipidated BSM, and a 30 
 Fig.  2. Analysis of tear fl uid PLTP during heparin affi nity separation. A: A two-step Heparin-Sepharose affi nity chromatography was used 
for PLTP isolation from tear fl uid (see “Experimental Procedures”). Tear fl uid (400 µl) was applied to the HiTrap Heparin column. The 
column was washed with buffer A (25 mM Tris-HCl buffer, pH 7.4 containing 1 mM EDTA), and 0.5 ml fractions were collected at a fl ow 
rate of 0.5 ml/min. Arrows show the start of 0.5 M and 2 M NaCl elution. The dotted gray line represents 280 nm absorbance readings for 
the collected fractions, and the black line shows PLTP activity from the corresponding fractions. The inset shows a Western blot image using 
MAb59 of the pooled 20–21 fractions (lane A) and fractions from the second HiTrap Heparin column affi nity chromatography where the 
20–21 fraction pool was run to the column and then eluted with a linear 0–0.5 M NaCl gradient (fl ow rate 0.5 ml/min; fraction size 0.5 ml). 
Fractions that contained active PLTP (36–39) were pooled and used for the proteomic analysis of copurifi ed proteins. PLTP activity was 
measured using a radiometric method described in “Experimental Procedures.” B: Silver stain of an SDS-PAGE gel separation of active 
PLTP-containing fractions after heparin affi nity separation of human tear fl uid. The pooled fractions from PLTP purifi cation were loaded 
on a 4–2% Bis-Tris NuPAGE gel (Invitrogen, CA). P1 represents nonbound material from the washing of the heparin column); P2 is con-
stituted from fractions containing active PLTP; and P3 is the fraction eluted with high-salt concentration. Arrow depicts the migration posi-
tion of mucins (for immunoblot images of tear fl uid mucins and PLTP see supplementary Fig. II). PLTP, phospholipid transfer protein; TF, 
tear fl uid. 
 Fig.  3. Interaction of PLTP with human tear fl uid mucins. Hu-
man tear fl uid (50   l) was incubated with rabbit polyclonal anti-
PLTP antibody (R290, 1 mg) in the presence of Protein G. The 
immunoprecipitate was recovered by low-speed centrifugation. 
Separation on nonreducing 5% SDS-PAGE was done for mucin. 
PLTP was analyzed using 12.5% SDS-PAGE under reducing condi-
tions. Lane 1: Human tear fl uid. Lane 2: Nonprecipitated superna-
tant fraction. Lane 3: Immunoprecipitate. A: Western blot analysis 
of mucin with monoclonal antibody MUC-5AC. PLTP was detected 
by monoclonal anti-PLTP Mab59 antibody (B). All immunoprecipi-
tation assays were repeated at least three times. PLTP, phospholipid 
transfer protein. 
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 PLTP is a member of the lipid transfer/lipopolysaccha-
ride binding protein family, which also includes CETP, 
the lipopolysaccharide binding protein (LBP), and bac-
tericidal/permeability increasing protein (BPI). Of these, 
CETP is absent from tear fl uid ( 10 ), while BPI is a lacrimal 
gland-derived, normal component of tear fl uid ( 21 ). The 
immunostaining pattern with specifi c monoclonal anti-
body against PLTP in lacrimal gland sections was very simi-
lar to that demonstrated for BPI ( 21 ), and also to that of 
tear fl uid lipocalin ( 22 ), suggesting that the lacrimal gland 
could be one of the sources for the tear fl uid PLTP. In-
deed, corneal epithelial cells also express PLTP at rela-
tively high levels (unpublished observations). 
 PLTP plays an essential role for lipid metabolism in the 
circulation, especially the transfer of postlipolytic phos-
pholipid-enriched surface remnants from triglyceride-rich 
particles, very low density lipoprotein (VLDL), and chylo-
microns (CM) to HDL is of utmost importance for the 
maintenance of proper HDL levels in the circulation ( 23 ). 
The concentration of PLTP in tear fl uid is at least 2-fold 
higher than PLTP in plasma, while the specifi c activity of 
PLTP in tear fl uid compared with plasma is signifi cantly 
lower ( 10 ). Both apolipoprotein (apo)A-I and apoE, which 
are capable of interacting with PLTP in plasma, are absent 
in tear fl uid; the role of these protein-protein interactions 
have been discussed previously ( 24 ). To elucidate other 
possible PLTP-protein interactions in tear fl uid, specifi c 
immunoprecipitation and binding assays were carried out. 
The heparin-bound active PLTP fractions were analyzed 
by MALDI-TOF mass spectrometry and revealed several 
candidate proteins: lactoperoxidase, lactotransferrin, 
proline-rich protein 1, lysozyme C, apoJ (clusterin), serum 
amyloid A, and lachryglobin. Of these proteins, apoJ and 
serum amyloid A, as well as PLTP and lipocalin, are known 
to interact avidly with phospholipids. Thus, complex for-
mation between these proteins seemed to be physiologi-
cally reasonable. Yet, further analysis using Western 
blotting could not confi rm binding of any of these pro-
teins to PLTP. Lysozyme and lactotransferrin are major 
tear fl uid proteins and most likely represent contaminants 
in the sensitive MALDI-TOF analysis. As PLTP does not 
show interaction with either of these proteins, it seems 
likely that in tear fl uid no other proteins are needed to 
maintain PLTP capable of transferring phospholipids. 
act with OVM in the absence of phospholipids and, there-
fore, sticks nonspecifi cally to the column matrix. 
 DISCUSSION 
 A recent analysis of the protein composition of the hu-
man tear fl uid revealed only 54 proteins that were identi-
fi ed with high confi dence ( 11 ). Yet, de Souza et al. were 
able to identify nearly 500 proteins in human tear fl uid 
using multiple mass spectrometric approaches ( 20 ). It 
seems that in the latter study, however, the authors may 
have had signifi cant contaminants from the ocular tissues. 
This is evidenced by the relatively large number of intra-
cellular proteins as well as the fact that not all of the major 
proteins, such as phospholipases, were found. The rela-
tively small amount of identifi ed proteins in the study of 
Li et al. ( 11 ) suggests a high stature for these key proteins 
in human tear fl uid. As the composition and functional 
regulation of tear fl uid remains largely unknown, it is im-
portant to characterize factors that play a role in the ho-
meostatic processes of tear fl uid, such as organization of 
lipids and viscoelasticity of tear fi lm. We have recently dis-
covered that human tear fl uid contains HA-PLTP protein 
( 10 ). Now we report that human tear fl uid PLTP is se-
creted from the lacrimal gland and that PLTP interacts 
with human ocular mucins as well as with mammalian-
derived mucin (BSM). This fi nding suggests a possible 
role for PLTP in the scavenging of lipophilic molecules 
from the ocular mucins and in maintaining the homeo-
stasis of the anterior tear lipid fi lm. This result does not 
contradict the recent fi ndings by Glasgow et al. that 
showed that tear fl uid lipocalin can effi ciently remove lip-
ids from the ocular surface ( 9 ). It seems unreasonable to 
assume that one protein is solely responsible for remov-
ing ocular contaminants in tear fl uid. Our current and 
previous results ( 10 ) suggest that, although PLTP is a mi-
nor constituent of normal tear fl uid, it possesses effi cient 
phospholipid transfer activity and likely aids lipocalin in 
decontaminating the ocular surface. We suggest that in 
tear fl uid, lipocalin and PLTP may act in concert to en-
sure effi cient lipid transfer. In line with Glasgow et al. ( 9 ), 
our results propose a role for PLTP in the fi ne-tuning of 
lipid transfer in tear fl uid. 
 Fig.  4. Binding of PLTP to mammalian-derived 
mucin BSM but not to avian-derived soluble form of 
ovomucin. BSM and soluble ovomucin were incorpo-
rated with increasing concentrations (0–45 µg/well) 
to nitrocellulose membranes and incubated with 
purifi ed PLTP (25 µg). Bound PLTP protein was 
detected by using monoclonal anti-PLTP Mab59 anti-
body. The data shown is background-corrected. Bind-
ing experiments were repeated at least three times. 
BSM, bovine submaxillary gland mucin; PLTP, phos-
pholipid transfer protein. 
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ity in plasma. One plausible explanation is that PLTP av-
idly binds phospholipids and this poorly phospholipidated 
form could maintain the active conformation. 
 Mucins are large glycoproteins that have at least 50–80% 
of their mass as carbohydrate. Mucin polypeptide chains, 
by defi nition, have domains rich in serine and threonine 
(STP, serine, threonine, and proline, tandem repeats), 
which provide  O- glycosidic linkage with oligosaccharides 
This assumption is also supported by fi ndings that during 
the normal PLTP purifi cation process from plasma, the 
fi nal, purifi ed PLTP protein does not contain any other 
copurifi ed proteins but is nevertheless highly active ( 16 ). 
Furthermore, human seminal plasma PLTP ( 25 ) and re-
combinant PLTP produced by baculovirus protein expres-
sion ( 26 ) are highly active. Neither of these systems 
contains apoA-I or apoE, which seems to regulate the activ-
 Fig.  5. Size exclusion chromatography of phospholipidated mucins (BSM and OVM) and PLTP. Elution profi le of the mucin-PC-PLTP 
sample in PBS (A and C) and in the presence of Tween 20 (0.05%) (B and D). Panel E represents SEC profi le for the nonlipidated OVM 
and PLTP comixture both in PBS and PBS-Tween. PLTP was incubated with the phospholipidated mucins (fi nal volume of the incubation 
mix was 0.830 ml) for 30 min at room temperature and applied onto the Superose 6HR column. Fractions (0.5 ml) were collected with a 
fl ow rate of 0.5 ml/min. Fractions were analyzed for radioactivity and protein content. Protein data was assessed using immunological dot-
blot system (described in “Experimental Procedures”) and quantifi ed by densitometry measurements (ImageJ v1.42q software). Results are 
presented as percentages relative to the total measured value considered as 100%. The arrow at the apparent molecular weight position of 
160 kDa depicts the elution position for active PLTP protein ( 15 ). SEC runs were repeated three times on average, and a representative run 
is presented. BSM, bovine submaxillary gland mucin; OVM, ovomucin; PLTP, phospholipid transfer protein; SEC, size exclusion chroma-
tography; V 0 , column void volume. 
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periments ( 24 ), where mucin formed complexes with a 
hydrodynamic diameter ranging from 25 to 225 nm (data 
not shown). 
 Tear lipocalin, a common tear lipoprotein, has been 
proposed to serve as a scavenger of lipophilic substances 
from the corneal surface ( 35 ). Lipocalin is capable of 
binding lipids in tear, and recently its ability to remove 
fl uorescently labeled lipids from the surface of the cornea 
has been shown ( 9, 36 ). Tear PLTP has lipid transfer abil-
ity without any acceptor molecule, and it is active without 
any detectable protein-protein association ( 26 ). On the 
basis of the current data, we suggest that a possible expla-
nation for the presence of PLTP in tear fl uid may be a 
scavenging property of PLTP: the lipid contamination 
from the surface layer of tear fi lm is directed to the ocular-
soluble and membrane-bound mucins. Here PLTP, inter-
acting with these mucins, can remove the harmful overload 
of lipids and transfer them to the lacrimal drainage sys-
tem. Alternatively, an intriguing possibility would be that 
because the anterior tear fl uid lipid fi lm possesses high 
quantities of phospholipids, PLTP could be responsible 
for transferring all or some of these lipids to the tear fl uid 
lipid layer. At present, we have no instrumentation to study 
this. 
 Our fi ndings suggest a notable role for PLTP in lipid 
transfer in human tears. Accordingly, PLTP could play a 
signifi cant role in preventing instability of the lipid fi lm 
and thus in preventing evaporative DES. The precise 
mechanisms of tear PLTP-facilitated phospholipid trans-
fer and association with mucin subtypes in the tear fl uid 
as well as the effect of PLTP blockage in the develop-
ment of DES must be further clarifi ed. To this end, we 
have recently used a PLTP knock-out mouse model to 
study the role of PLTP in DES. Our preliminary data 
demonstrate that these mice develop considerable DES 
with concomitant histological changes and increased cor-
neal epithelial permeability (Setälä et al., unpublished 
observations). Clarifi cation of the role of PLTP in the de-
velopment of DES will be the goal of our near-future 
studies.  
 The authors would like to thank Sari Nuutinen for excellent 
technical assistance. 
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